# Niacin, N-3 Fatty Acids and Insulin Resistance

> **NCT00286234** · PHASE4 · COMPLETED · sponsor: **University of South Dakota** · enrollment: 68 (actual)

## Conditions studied

- Metabolic Syndrome
- Hypertriglyceridemia

## Interventions

- **DRUG:** omega-3 acid ethyl esters
- **DRUG:** extended release niacin
- **DRUG:** placebo
- **DRUG:** omega-3 acid ethyl esters
- **DRUG:** combined treatment

## Key facts

- **NCT ID:** NCT00286234
- **Lead sponsor:** University of South Dakota
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-10
- **Primary completion:** 2008-08
- **Final completion:** 2008-12
- **Target enrollment:** 68 (ACTUAL)
- **Last updated:** 2021-10-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00286234

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00286234, "Niacin, N-3 Fatty Acids and Insulin Resistance". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00286234. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*